December 2003
Worldwide Biotech;Dec2003, Vol. 15 Issue 12, p2
Trade Publication
Presents a study that examined the efficacy and safety of the therapeutic angiogenic product Ad5FGF-4 in improving blood flow in patients with ischemic heart disease in Germany.


Related Articles

  • Sema3E--Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. Casazza, Andrea; Finisguerra, Veronica; Capparuccia, Lorena; Camperi, Andrea; Swiercz, Jakub M.; Rizzolio, Sabrina; Rolny, Charlotte; Christensen, Claus; Bertotti, Andrea; Sarotto, Ivana; Risio, Mauro; Trusolino, Livio; Weitz, Jurgen; Schneider, Martin; Mazzone, Massimilano; Comoglio, Paolo M.; Tamagnone, Luca // Journal of Clinical Investigation;Aug2010, Vol. 120 Issue 8, p2684 

    Semaphorin 3E (Sema3E) is a secreted molecule implicated in axonal path finding and inhibition of developmental and postischemic angiogenesis. Sema3E is also highly expressed in metastatic cancer cells, but its mechanistic role in tumor progression was not understood. Here we show that...

  • Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis. Chen, Xing-Lin; Lei, Ying-Hong; Liu, Cun-Fei; Yang, Qun-Fang; Zuo, Pei-Yuan; Liu, Cheng-Yun; Chen, Chang-Zhong; Liu, Yu-Wei // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Concerns have arisen regarding the risk of ischemic heart disease with the novel antiangiogenic agent bevacizumab, a recombinant humanised monoclonal antibody to the vascular endothelial growth factor that is widely used in cancer treatment. Currently, the role of bevacizumab in ischemic heart...

  • Review: Aspirin reduces CAD events in persons with no history of cardiovascular disease, but it increases gastrointestinal bleeding. Jain, Meera; Rosenberg, Mark // ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p6 

    Provides information on a study that examined the benefits and harms of aspirin use to prevent coronary artery disease events in persons with no history of cardiovascular disease. Data sources; Study selection; Data extraction; Main results; Conclusions.

  • The endothelium: a new target for therapy. Cooke, J.P. // Vascular Medicine;2000, Vol. 5 Issue 1, p49 

    At one time considered merely a monolayer of cells lining the vascular conduit, the endothelium has emerged recently as an organ with functions as complex as any in the body. A highly active regulatory organ, the endothelium senses and assesses the hemodynamic, humoral, and inflammatory signals...

  • Selective COX-2 inhibition improves endothelial function in coronary artery disease. Prabhakaran, Dorairaj; Anand, Sonia S // Vascular Medicine;2003, Vol. 8 Issue 1, p63 

    Question: What are the effects of celecoxib, a selective COX-2 inhibitor on endothelial function? Population: Fourteen male patients (46�77 years) with severe coronary artery disease and chronic stable angina who did not have a coronary revascularization procedure three months prior to...

  • MR Angiography to Assess Coronary Artery Disease. Zepf, Bill // American Family Physician;7/1/2002, Vol. 66 Issue 1, p156 

    Presents information on a prospective, multicenter, international study to evaluate the clinical usefulness of magnetic resonance angiography (MRA) in the diagnosis of coronary heart disease. Background on invasive and noninvasive techniques in identifying coronary artery disease; Reliability...

  • Obesity and Heart Disease: The Last Great Risk Factor? Rippe, James M. // Nutrition in Clinical Care;Jan/Feb98 Supplement 1, Vol. 1 Issue 1, p1 

    Focuses on the relationship of obesity and coronary heart disease (CHD) in the United States. Consideration of obesity as a risk factor for CHD; Percentage of obese adult population in the country; Increase of the risk for the development of CHD.

  • Obesity as a Risk Factor for Heart Disease: An Overview. Rippe, James M. // Nutrition in Clinical Care;Jan/Feb98 Supplement 1, Vol. 1 Issue 1, p3 

    Presents an overview related to the relationship of obesity with coronary heart disease (CHD) in the United States. Prevalence of obesity in the country; Consideration of obesity as a strong and independent factor for CHD; Promotion of the clustering of multiple CHD risk factors due to obesity.

  • Combined Endovascular Treatment of a Descending Thoracic Aortic Aneurysm and Off-Pump Myocardial Revascularization. Moura, Marcelo R.L.; Melissano, Germano; Maisano, Francesco; Marone, Enrico M.; Civilini, Efrem; Alfieri, Ottavio; Chiesa, Robert // Vascular & Endovascular Surgery;Jul/Aug2002, Vol. 36 Issue 4, p305 

    Presents a case study of a 76-year-old man with severe coronary artery disease and a thoracic aneurysm. Background on the incidence of aneurysmatic disease of the thoracic aorta; Medical history of the patient; Diagnosis and treatment.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics